Keywords: merck, co, pays, premium, buy, sirna, therapeutics

Merck & Co pays 100% premium to buy Sirna Therapeutics for $1.1 billion

Article | 06 November 2006

Print This

*p US pharmaceutical major Merck & Co is to pay a premium of nearly 102% to acquire Sirna Therapeutics, a publicly-held biotechnology ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in